Pharmaceutical

Bellicum Pharmaceuticals (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the fourth quarter and full year ended December 31, 2017. As quoted in the press release: “In the past year, we made substantial progress toward our vision of delivering cures through controllable cell …

Bellicum Pharmaceuticals (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

“In the past year, we made substantial progress toward our vision of delivering cures through controllable cell therapy,” said Bellicum’s President & CEO Rick Fair. “We completed enrollment in our first registrational trial of BPX-501 and remain on track for our first filing for product approval in Europe in 2019. We moved three new projects featuring our industry-leading cellular control technology into clinical trials, including the first-ever GoCAR-T with our iMC activation switch. We also made substantial preclinical progress on our next generation ‘dual-switch’ platform containing both activation and safety switches in the same CAR-T cell, and initiated plans to move two dual-switch CAR-T projects into clinical trials in 2019.”

Click here to read the full press release.

MARKETS

Markets
TSX19577.04+31.10
TSXV660.08+4.88
DOW32726.82-85.68
S&P 5004151.94-3.23
NASD12720.58+52.42
ASX6974.90-1.00

COMMODITIES

Commodities
Gold1786.63-6.46
Silver20.06-0.14
Copper3.50+0.02
Palladium2101.76+37.76
Platinum940.53+9.54
Oil88.76+0.22
Heating Oil3.25-0.09
Natural Gas8.10-0.02

DOWNLOAD FREE REPORTS

×